Robert Brodsky, President of American Society of Hematology and Chief of Hematology at Johns Hopkins, shared an article by Adetola A. Kassim, et al. on X:
“Out in NEJM Evidence today.
KEY TAKEAWAYS:
- Of 42 people with severe SCD who had the procedure , 95% were alive at 2 yrs, and 88% are considered cured.
- Most people with SCD are eligible, which costs a fraction of the price of gene editing/therapy.
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.
Authors: Adetola A. Kassim, et al.
